Phibro Animal Health Corporation — Q1 FY2024 Form 10-Q
Business context and reporting period
Phibro develops, manufactures and markets animal health, mineral nutrition and performance products for food and companion animals and industrial customers. This unaudited quarterly report covers the three months ended September 30, 2023, compared with the three months ended September 30, 2022.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Net sales | $231.3 million | $232.5 million | Down 1% |
| Gross profit / margin | $67.7 million / 29.3% | $68.6 million / 29.5% | Down $0.9 million |
| Operating income (loss) | $(0.7) million | $13.7 million | Down $14.4 million |
| Net income (loss) | $(8.0) million | $3.9 million | Down $11.9 million |
| Diluted EPS | $(0.20) | $0.10 | Down $0.30 |
| Adjusted EBITDA | $18.7 million | $22.1 million | Down 16% |
| Adjusted net income | $5.5 million | $8.3 million | Down 33% |
| Adjusted diluted EPS | $0.14 | $0.21 | Down 33% |
| Cash flow from operations | $16.2 million | $(10.7) million | Improved $26.9 million |
Animal Health sales increased 4% to $160.5 million, led by vaccines, nutritional specialties and ethanol-processing aids. Mineral Nutrition sales declined 6% to $56.0 million because of lower prices, volumes and demand. Performance Products sales declined 18% to $14.8 million because of weaker personal-care ingredient demand.
Financial condition, debt and liquidity
- Cash and cash equivalents were $43.2 million; short-term investments were $48.0 million, for combined cash and short-term investments of $91.2 million.
- Working capital was $345.1 million, and management reported a 3.33:1 current-assets-to-current-liabilities ratio.
- Debt consisted of $154.0 million drawn on the revolver, $24.2 million of current debt maturities and $304.7 million of long-term debt, before considering related debt issuance costs and other presentation items.
- The revolver had $153.5 million of remaining availability after $2.5 million of letters of credit, subject to covenant and facility restrictions.
- The credit facilities mature in April 2026. The company was in compliance with its financial covenants at September 30, 2023.
- Capital expenditures were $7.5 million. The company paid $4.9 million in dividends and declared an additional $0.12-per-share dividend payable December 20, 2023.
Material changes versus the prior comparable period
- SG&A increased 25% to $68.5 million, including a $10.4 million pension settlement charge and $0.1 million of stock-based compensation. Excluding those items, SG&A increased approximately $3.0 million.
- The pension charge resulted from a July 2023 annuity purchase that transferred approximately $26.4 million of pension obligations to an insurer and required recognition of previously accumulated pension losses.
- Net interest expense increased 49% to $4.6 million because of higher debt and variable interest rates.
- Foreign currency losses increased to $6.7 million from $5.2 million, primarily because of currency fluctuations in Argentina and Brazil.
- Animal Health adjusted EBITDA increased 6% to $28.5 million, but Mineral Nutrition adjusted EBITDA fell 46% to $2.9 million and Performance Products adjusted EBITDA fell 40% to $1.4 million. Corporate costs increased to $14.1 million from $12.5 million.
- The company generated operating cash flow despite the GAAP net loss, aided by working-capital movements, including a $12.8 million receivables benefit.
Guidance, outlook, commentary and risks
The filing does not provide specific financial guidance. Management expects cash on hand, operating cash flows and available financing to support ongoing needs for at least the next twelve months, but cautions that adverse operating performance, covenant violations, economic conditions or financing-market disruptions could reduce liquidity.
- Israel conflict: Phibro has three manufacturing sites and an office in Israel, with approximately 550 employees. Israeli operations represented 27% of consolidated assets and 19% of consolidated net sales for the quarter. The company reported some disruption but stated that it currently expects to meet supply commitments. Escalation could affect facilities, personnel, raw materials, logistics and customers.
- Carbadox/Mecadox regulatory exposure: In November 2023, the FDA notified the company of a final order revoking the approved residue-detection method and proposed withdrawal of approvals for carbadox products. Phibro intends to seek a hearing and defend the product. Mecadox sales were approximately $20 million for the twelve months ended September 30, 2023; the product remained available as of the filing date.
- Environmental contingencies: Estimated environmental investigation, remediation and closure liabilities were approximately $8.5 million. A February 2023 settlement concerning the Omega Chemical groundwater matter contemplated payments through February 2024 and remained subject to formal regulatory and court approval.
- Interest-rate and currency risk: A $300.0 million interest-rate swap effectively fixes the floating portion of related debt at 0.61% through June 2025. The company remains exposed to foreign exchange, interest-rate and commodity-price volatility.
- Other principal risks include animal disease outbreaks, restrictions on antibacterials, raw-material availability and pricing, supply-chain disruption, competition, regulatory approvals, substantial indebtedness and debt covenants.
Important facts for investors to verify
- Whether the FDA ultimately withdraws carbadox approvals and the potential effect on approximately $20 million of annual Mecadox sales.
- The operational and financial effects of the Israel conflict, given the concentration of assets, sales and manufacturing capacity in Israel.
- Whether Mineral Nutrition and Performance Products demand and margins recover after their Q1 declines.
- Progress in reducing corporate costs, foreign-currency losses and interest expense.
- Compliance with leverage and interest-coverage covenants as debt maturities approach in April 2026.
- Final approval, payment obligations and any changes to the estimated $8.5 million environmental liability.
- Reconciliation and appropriate interpretation of non-GAAP Adjusted EBITDA and adjusted net income, which exclude significant items and are not standardized under GAAP.